Novartis AG plans to acquire the remaining shares of Speedel Holding AG for approximately $881 million, according to a company statement. Novartis currently holds 61.4% of the company. The acquisition would give Novartis full control over the promising blood-pressure drug Tekturna that Speedel helped develop, and Novartis would no longer have to pay Speedel licensing fees.     Tekturna was launched in the U.S. last year and Novartis expects that it will eventually replace its blockbuster blo...